Market Update (NASDAQ:AMGN): UK cost watchdog turns down Amgen’s new cholesterol drug

[Reuters – UK Focus] – Amgen (Xetra: 867900 – news) ‘s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the . . . → Read More: Market Update (NASDAQ:AMGN): UK cost watchdog turns down Amgen’s new cholesterol drug Similar Articles: Company Update (NASDAQ:AMGN): Europe gets Amgen cholesterol drug for 50-60 pct of U.S. price Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-risk patients Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week